Trial Profile
CD19-targeting CAR T Cell Therapy in the Treatment of Relapsed or Refractory CD19 Positive B-cell Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs GC 007F (Primary)
- Indications Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 03 Nov 2020 Planned End Date changed from 31 Dec 2019 to 31 Dec 2021.
- 03 Nov 2020 Planned primary completion date changed from 30 Sep 2019 to 30 Nov 2021.
- 27 Jun 2018 New trial record